About FPR – Who We Are

Forerunner Pharma Research Co., Ltd. (FPR) was established as a joint venture by Chugai Pharmaceutical Co., Ltd., Mitsui & Co., Ltd., and the Central Institute for Experimental Animals in April 2005. FPR wishes to pursue more effective approaches for antibody drug discovery by means of pathophysiological studies of diseases and genomic information. With its research base located favorably at the Komaba Open Laboratory of the University of Tokyo, FPR is in an advantageous position for utilizing the latest findings of academic centers and other institutions in addition to pharmaceutical technologies of Chugai. It has been pursing explorative research for innovative drugs by identification and evaluation of new target molecules. FPR established a new research laboratory at the Yokohama Bio Industry Center in September 2010 to extend drug discovery research, and started joint research in the search for molecular targeted drugs with the Independent Administrative Institute (Riken, Japan). In October 2011, FPR made a new start as a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. In the increasingly competitive environment of new drug development, FPR will conduct research in the exploration of new pharmaceutical targets.

Research on epigenomes, transcription factors, and cancer stem cells will expand the research network of FPR and contribute to the development of new drugs using innovative approaches.

About Chugai Pharmaceutical Co., Ltd. (Chugai)

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy unmet medical needs, mainly focusing on the oncology area.

↑ Page Top